⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20248114 | 1.00 | — | — | |
| SCHEMBL786094 | 1.00 | — | — | |
| SCHEMBL788544 | 1.00 | — | — | |
| SCHEMBL788707 | 0.94 | KDM4E (0.32) | — | |
| SCHEMBL788724 | 0.94 | KDM4E (0.32) | — | |
| SCHEMBL18684794 | 0.89 | KDM4E (0.36) | — | |
| SCHEMBL804989 | 0.89 | KDM4E (0.36) | — | |
| SCHEMBL18684795 | 0.89 | KDM4E (0.36) | — | |
| SCHEMBL20248233 | 0.87 | — | — | |
| SCHEMBL788624 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270303-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20190263860-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-9220748-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8648037-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |